{"schema_version":"secwatch.filing_event.v1","accession":"0001810182-25-000006","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.071182+00:00","generated_at":"2026-05-17T06:45:38.334870+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ALX Oncology: CMO Alan Sandler resigns, Barbara Klencke appointed Interim CMO; Nasdaq compliance regained","bullets":["Alan Sandler resigns as CMO effective Sep 26, 2025, returns to Board as director.","Barbara Klencke steps down from Board to become Interim CMO effective Sep 17, 2025.","ALX regained Nasdaq minimum bid price compliance (closing bid >= $1 for 10 consecutive days through Sep 4, 2025).","Board committee changes: R&D committee paused; new Audit, Compensation, and Governance committee assignments approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001810182-25-000006","json":"https://secwatch.observer/filing/0001810182-25-000006.json","markdown":"https://secwatch.observer/filing/0001810182-25-000006.md","text":"https://secwatch.observer/filing/0001810182-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000181018225000006/0001810182-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000181018225000006/alxo-20250911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:45:38.334870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}